Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Key Highlights
- ➤Phase 2b CORAL results accepted for oral presentation at CHEST 2026
- ➤CORAL trial randomized 165 IPF chronic-cough patients across three nalbuphine ER doses and placebo
- ➤Nalbuphine ER evaluated over six weeks in double-blind, placebo-controlled Phase 2b trial
- ➤Trevi develops Haduvio for chronic cough in IPF, non-IPF ILD, and RCC
Expert Statements
Philip Molyneaux, MD, PhD; CORAL trial oral presentation presenter
“Patient-Reported Outcomes Show Early and Sustained Improvement Following Nalbuphine Extended-Release in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough”
NEW HAVEN, Conn., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that results from the Phase 2b CORAL trial were accepted as an oral presentation at the CHEST 2026 Annual Meeting of the American College of Chest Physicians, taking place from October 18 – 21, 2026, in Phoenix, Arizona.
Abstract: Patient-Reported Outcomes Show Early and Sustained Improvement Following Nalbuphine Extended-Release in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough Oral Presentation Session: 4175 – ILD: Treatment Updates Date & Time: October 20, 1:45 p.m. – 2:30 p.m. MST Location: Phoenix Convention Center Exhibit Hall Rapid Fire Area 2D Presenter: Philip Molyneaux, MD, PhD
Get started
Create a free account to read the full story.